




RealRate

PHARMACEUTICAL 2022

InMed Pharmaceuticals Inc.
Rank 422 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of InMed Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of InMed Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 41% points. The greatest weakness of InMed Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 321% points.

The company's Economic Capital Ratio, given in the ranking table, is -532%, being 256% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	8,378
Cost of Goods Sold	0
Intangible Assets	1,062
Liabilities, Current	2,215
Liabilities, Non-Current	189
Other Assets	15
Other Compr. Net Income	430
Other Expenses	121
Other Liabilities	0
Other Net Income	-265
Property and Equipment	327
Research and Development	5,338
Revenues	0
Selling, General and Administrative Expense	4,479

Output Variable	Value in 1000 USD
Assets	9,781
Liabilities	2,405
Expenses	9,938
Stockholders Equity	7,377
Net Income	-10,203
Comprehensive Net Income	-9,988
Economic Capital Ratio	-532%